Genzyme Team Reports Proof-of-concept Data for Expressed RNAi Huntington's Therapy | GenomeWeb

NEW YORK (GenomeWeb) – Researchers from Genzyme this month reported new proof-of-concept data showing that an expressed RNAi approach could be used to both prevent and treat the manifestations of Huntington's disease (HD) in an animal model of the condition.

Though promising, the work is still early stage, cautioned Lisa Stanek, lead author of the study. And while the company is continuing to develop the RNAi-based treatment for HD, clinical studies remain years away, she said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.